Oragenics Inc (OGEN)
0.314
+0.02
(+5.76%)
USD |
NYAM |
Nov 04, 16:00
0.3148
0.00 (0.00%)
Pre-Market: 09:05
Oragenics Research and Development Expense (Annual): 15.49M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 15.49M |
| December 31, 2022 | 10.07M |
| December 31, 2021 | 10.59M |
| December 31, 2020 | 22.11M |
| December 31, 2019 | 12.12M |
| December 31, 2018 | 5.972M |
| December 31, 2017 | 3.540M |
| December 31, 2016 | 4.755M |
| December 31, 2015 | 8.734M |
| December 31, 2014 | 3.065M |
| December 31, 2013 | 9.359M |
| Date | Value |
|---|---|
| December 31, 2012 | 7.861M |
| December 31, 2011 | 2.449M |
| December 31, 2010 | 2.015M |
| December 31, 2009 | 1.834M |
| December 31, 2008 | 1.956M |
| December 31, 2007 | 1.570M |
| December 31, 2006 | 2.024M |
| December 31, 2005 | 2.097M |
| December 31, 2004 | 1.991M |
| December 31, 2003 | 0.9294M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
10.07M
Minimum
2022
22.11M
Maximum
2020
14.08M
Average
12.12M
Median
2019
Research and Development Expense (Annual) Benchmarks
| Shuttle Pharmaceuticals Holdings Inc | 3.517M |
| Perspective Therapeutics Inc | 21.31M |
| Alaunos Therapeutics Inc | 16.28M |
| Cocrystal Pharma Inc | 15.17M |
| Cara Therapeutics Inc | 108.51M |